Mobile Menu

THE definitive guide on sequencing technology platforms


The annual Sequencing Buyer’s Guide has become the go-to guide for helping people in the genomics space understand the sequencing landscape, save time and money, and make better purchasing decisions. 

Now in its third edition, we’ve again worked with David Smith, Emeritus Professor of the Mayo Clinic to produce the guide. You can download the report for free here.

Who is this report for?

This report is for anyone interested in:

  • How different sequencing technologies work – the underlying mechanisms.
  • How to evaluate the strengths, weaknesses and applications of different sequencing platforms.
  • Gathering information prior to purchasing a sequencer or choosing a sequencing service partner.
  • Reducing the cost of sequencing and improving their sequencing workflow.
  • The patent landscape for sequencing.
  • Getting a glimpse of the future of sequencing.

About the author

David Smith is Emeritus Professor of the Mayo Clinic, who until very recently headed up the Technology Assessment Group for the Mayo Clinic for Individualized Medicine. He is an expert in next generation sequencing technologies. 


Chapters within the guide include:

First Generation MPS Technologies

An overview of first gen MPS technologies, including those that utilise emulsion PCR, the QIAGEN sequencing platform, GenapSys, Illumina and BGI.

Second Generation MPS Technologies

A outline of second gen MPS technologies, including those of Pacific Biosciences, Oxford Nanopore Technologies and Roswell Biotechnology. 

Getting Into MPS For Less

Developing sequencing capabilities has traditionally been very expensive. This chapter will provide thoughts on how to do it for less.

The MPS Patient Landscape

A brief outline of some of the recent patent disputes in the sequencing space, with thoughts on what they might mean for buyers.

What Do You Want To Use MPS For?

Advice on how and when to use different sequencing approaches, including whole genome and exome sequencing, targeted genomic sequencing, RNA sequencing, epigenetic sequencing, microbiome sequencing and liquid biopsy.

The Future of MPS

Some predictions on where the sequencing landscape is heading.


Share this report